BioCentury
ARTICLE | Clinical News

NGX426: Phase I data

December 8, 2008 8:00 AM UTC

In a double-blind Phase I trial in 18 healthy volunteers, 150 mg of NGX426 met the co-primary endpoints of significant reductions in spontaneous pain, hyperalgesia and allodynia vs. placebo. A 90 mg d...